GLP-1 Drug Interactions

Summary: GLP-1 receptor agonists rarely cause classic CYP450 drug interactions, but they slow gastric emptying, which changes how oral drugs are absorbed and stacks hypoglycemia risk with insulin and sulfonylureas.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

GLP-1 receptor agonists do not get metabolized through the CYP450 enzymes that drive most classic drug interactions, so the labels for Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, and Rybelsus list very few "do not combine" warnings ^[1][3][4]. The real interaction story is different. GLP-1s slow gastric emptying. That single mechanism changes how fast oral drugs get absorbed, and it also stacks with anything else that lowers blood sugar. Most of what your prescriber actually monitors flows from those two facts.

This page walks the class through interaction by interaction, with the FDA label position on each.

The one mechanism that drives most GLP-1 interactions

GLP-1 receptor agonists slow gastric emptying. Food and pills stay in the stomach longer before entering the small intestine where most absorption happens. For an injectable GLP-1 like semaglutide or tirzepatide, this effect peaks in the first weeks of treatment and partially attenuates over time, but it never fully goes away ^[4].

For oral drugs, the pharmacokinetic consequence is predictable. The time to maximum plasma concentration (tmax) gets delayed, and the peak concentration (Cmax) drops. The total drug exposure across the dosing interval (the AUC, area under the curve) is usually unchanged. A 2024 systematic review in Drug Safety pooled 22 reports across exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, and semaglutide and concluded that for most oral medications, the AUC changes were not clinically meaningful and dose adjustments are not required ^[4].

The exceptions are drugs with a narrow therapeutic index or drugs whose efficacy depends on a sharp Cmax. Those are the ones worth paying close attention to.

Insulin and sulfonylureas: hypoglycemia stacking

This is the most clinically important GLP-1 interaction and the one every prescriber thinks about first. GLP-1 receptor agonists lower blood glucose through glucose-dependent insulin secretion and glucagon suppression. Insulin and sulfonylureas (glipizide, glyburide, glimepiride) lower blood glucose directly. Stack them and the hypoglycemia risk rises sharply.

The Ozempic, Wegovy, Mounjaro, and Victoza labels all carry the same warning: when adding the GLP-1 to an insulin or sulfonylurea regimen, consider lowering the dose of the insulin or sulfonylurea to reduce hypoglycemia risk ^[1][3][5]. In SUSTAIN-5, adding semaglutide to insulin produced documented symptomatic hypoglycemia in over 11 percent of patients on the higher dose ^[1]. The fix is preemptive dose reduction of the secretagogue or basal insulin at GLP-1 initiation, not waiting for the first hypo event.

Practical pattern most endocrinologists use:

• Sulfonylurea: cut the dose roughly in half when starting a GLP-1, or stop the sulfonylurea entirely if A1c is near target.
• Basal insulin: reduce by 20 percent if A1c is at or below 8, hold steady if A1c is above 8 and adjust based on fasting glucose response.
• Mealtime insulin: typically untouched at GLP-1 start, then re-evaluated as appetite drops and weight comes down.

DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin, alogliptin) work upstream by preventing breakdown of endogenous GLP-1. Combining a DPP-4 inhibitor with a GLP-1 receptor agonist is not recommended. The mechanisms overlap, there is no additional A1c benefit, and you are paying for two drugs to do one job. Most US guidelines stop the DPP-4 when starting a GLP-1.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are a different story. They work through glucose excretion in urine, not insulin secretion. Combining a GLP-1 and an SGLT2 inhibitor is well-supported and produces additive A1c, weight, and cardiovascular benefits. No interaction adjustment needed. Metformin combination is also fine and is in fact the default starting pair for most type 2 diabetes treatment plans.

Warfarin and INR monitoring

Warfarin is the textbook example of a narrow therapeutic index drug, and it lives squarely in the gastric emptying interaction zone. The 2024 systematic review found that all studied GLP-1s (exenatide, lixisenatide, albiglutide, dulaglutide, semaglutide) delayed warfarin tmax and produced minor Cmax reductions, but the AUC and the INR pharmacodynamic endpoint were not meaningfully changed ^[4].

So why monitor? Because real-world warfarin patients are not the healthy young volunteers in pharmacokinetic studies. They have variable diets, variable kidney function, and variable adherence. The FDA Ozempic label specifically recommends frequent INR monitoring when initiating or changing the dose of semaglutide in patients on warfarin ^[1]. Most cardiologists check INR weekly for the first month after GLP-1 initiation, then settle back into the patient's normal interval.

The same caution applies to apixaban, rivaroxaban, and edoxaban (the direct oral anticoagulants), though these have wider therapeutic windows and do not require INR checks. Watch for unusual bruising or bleeding in the first few months of GLP-1 therapy on any anticoagulant.

Oral contraceptives, especially Rybelsus

Combined oral contraceptives are the second narrow-window oral interaction worth knowing. The fear is straightforward: if a GLP-1 reduces estrogen or progestin absorption below the contraceptive threshold, pregnancy risk goes up.

For injectable GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity), the pharmacokinetic data are reassuring. Studies with exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, and semaglutide all showed reduced Cmax and delayed tmax of ethinylestradiol and the progestin component, but the AUC stayed within bioequivalence range and the minimum trough concentrations were preserved ^[4]. The FDA labels for these injectables do not require contraceptive dose changes.

Rybelsus (oral semaglutide) is the exception. Because Rybelsus itself is an oral drug that requires a near-empty stomach and a strict 30-minute window before any other oral intake, taking a birth control pill within that window will reduce the contraceptive's absorption. The Rybelsus label tells patients to take Rybelsus at least 30 minutes before any other oral medication, including oral contraceptives ^[2]. There is no specific contraceptive failure warning, but reproductive health pharmacists generally recommend a backup method (condoms) for the first cycle on Rybelsus and a same-time-every-day dosing schedule thereafter.

Tirzepatide (Mounjaro, Zepbound) carries a unique warning for oral contraceptives. Because tirzepatide acts on both GIP and GLP-1 receptors and slows gastric emptying more profoundly at initiation, the label recommends that patients on oral hormonal contraceptives switch to a non-oral method or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation ^[3]. This is the strongest contraceptive warning on any GLP-1 label.

Thyroid medications: timing matters with Rybelsus

Levothyroxine is the most prescribed thyroid medication in the United States, and the interaction concern is again narrow therapeutic index plus a strict absorption window. Levothyroxine itself needs to be taken on an empty stomach, away from food, calcium, iron, and many other drugs.

For injectable GLP-1s, levothyroxine absorption is delayed in the same predictable way as other oral drugs, but the TSH endpoint usually stays in range and most endocrinologists do not adjust the levothyroxine dose at GLP-1 initiation. Monitor TSH at the next routine check and adjust if needed.

Rybelsus and levothyroxine is a harder timing problem. Both drugs need an empty stomach. Both need a window before any other intake. The Rybelsus label notes that semaglutide increased levothyroxine total exposure (AUC) by 33 percent in a pharmacokinetic study, which is large enough to push some patients into mild hyperthyroidism without monitoring ^[2]. The recommendation is to monitor thyroid function in patients on levothyroxine who start Rybelsus. The practical scheduling that works: take Rybelsus first thing in the morning with a sip of water, wait 30 minutes (or 60 if possible), then take levothyroxine, then wait another 30 minutes before food or coffee. It is annoying. Many patients with both conditions switch to injectable semaglutide to avoid the timing puzzle.

Opioids: additive GI slowdown

GLP-1 receptor agonists slow gastric emptying. Opioids slow gastrointestinal motility throughout the gut, particularly through the colon, producing the constipation that defines opioid bowel syndrome. Stack them and you get worse nausea, worse constipation, and a higher risk of GI obstruction or gastroparesis flare.

The FDA Ozempic and Wegovy labels do not contraindicate opioid use, but they note that GLP-1 receptor agonists slow gastric emptying and that delayed gastric emptying may impact the absorption of concomitantly administered oral medications ^[1]. Surgical and anesthesia guidelines now address this directly: the American Society of Anesthesiologists recommends holding the GLP-1 the morning of (daily formulations) or for 1 week before (weekly formulations) elective surgery to reduce aspiration risk from retained gastric contents, particularly relevant when opioids are part of the perioperative plan.

For chronic opioid users starting a GLP-1, expect more nausea than a typical patient and plan a more aggressive bowel regimen (a stimulant laxative, hydration, and dietary fiber). For acute opioid use after surgery in patients already on a GLP-1, the prescribing surgeon should know about the GLP-1.

Other incretin drugs: do not stack

This rule is short. Do not combine two GLP-1 receptor agonists. Do not combine a GLP-1 with a tirzepatide. Do not combine a GLP-1 with a DPP-4 inhibitor. The mechanisms overlap, no head-to-head trial has shown additive benefit, and the side effect profile compounds.

Switching from one GLP-1 to another, or from a GLP-1 to tirzepatide, requires a washout period. Most prescribers wait one full dosing interval (one week for semaglutide and tirzepatide, three days for daily liraglutide) before starting the new drug at its starting dose. Do not titrate up from the equivalent of the old drug; restart from the bottom and titrate as if you are a new patient. This avoids stacking the residual effect of the prior drug with the initial nausea of the new one.

MAOIs and SSRIs: serotonin syndrome theoretical concern

GLP-1 receptor agonists have no direct serotonergic activity, but the labels for Saxenda and Wegovy (the obesity formulations of liraglutide and semaglutide) carry a class warning shared with most weight loss drugs: the potential for serotonin syndrome when used with SSRIs, SNRIs, MAOIs, triptans, or tramadol ^[1][5]. This warning is precautionary. There is no robust signal in the published pharmacovigilance data.

In practice, SSRIs (Prozac, Zoloft, Lexapro, Paxil, Celexa) and SNRIs (Cymbalta, Effexor) are commonly co-prescribed with GLP-1s and the combination is considered safe. MAOIs (Nardil, Parnate) are uncommon today, but if a patient is on one, the prescribing psychiatrist should know about the GLP-1 and watch for early signs of serotonin syndrome (agitation, tachycardia, tremor, hyperreflexia) during dose escalation. Wellbutrin (bupropion) is not serotonergic and is often paired with GLP-1s for weight loss without concern. Buspirone has mild serotonergic activity and is generally fine to combine.

ADHD stimulants (Adderall, Vyvanse, Concerta, Ritalin) are not contraindicated with GLP-1s. The combination is common in clinical practice. The interaction concern is appetite suppression stacking. Both drug classes reduce appetite, and patients sometimes underconsume calories enough to feel weak or dizzy. Most prescribers ask patients to track daily protein intake and water intake when running both drugs.

Mood stabilizers and antipsychotics (Abilify, Seroquel, Lamictal, lithium, Topamax) are also fine to combine with GLP-1s mechanistically, but lithium has a narrow therapeutic index and gets delayed by GLP-1 gastric slowing. Check a lithium level at 4 to 6 weeks after GLP-1 initiation.

Antibiotics: delayed absorption, watch the narrow-window ones

GLP-1s delay tmax of oral antibiotics, but most antibiotics have wide therapeutic windows and do not change clinical efficacy meaningfully. The exceptions worth flagging:

• Fluoroquinolones (ciprofloxacin, levofloxacin) and macrolides (azithromycin, clarithromycin) can cause hypoglycemia as a class effect. When stacked with a GLP-1 plus insulin or sulfonylurea, hypoglycemia risk rises. Monitor.
• Penicillins and cephalosporins absorb normally and need no adjustment.
• Oral vancomycin has local activity in the gut, not systemic, so absorption changes do not matter clinically.
• Doxycycline and tetracyclines have multiple food and mineral interactions independent of GLP-1s; the usual rules apply.

For acute illness requiring antibiotics, no GLP-1 dose change is needed. For chronic suppressive antibiotic therapy in a patient on a GLP-1, the prescribing clinician should be aware.

Grapefruit: no direct interaction, but consider

Grapefruit juice inhibits CYP3A4 and is famous for spiking the concentration of statins, calcium channel blockers, and several other drugs. GLP-1s are not metabolized by CYP3A4, so there is no direct grapefruit interaction with semaglutide, tirzepatide, liraglutide, dulaglutide, or exenatide. You can drink grapefruit juice with any GLP-1.

The indirect consideration is that grapefruit juice will boost the levels of other drugs in your regimen if those drugs are CYP3A4 substrates. Statins (atorvastatin, simvastatin) are the most common case, and many patients on a GLP-1 are also on a statin. The grapefruit warning, if applicable, comes from the statin label, not the GLP-1 label.

Bariatric surgery plus GLP-1

This is not a drug interaction in the classic sense, but it changes how the GLP-1 is metabolized and absorbed and is worth understanding. Patients who have had sleeve gastrectomy, Roux-en-Y gastric bypass, or other bariatric procedures have anatomically altered stomachs. Gastric emptying is already accelerated (after sleeve) or bypassed (after RYGB). The gastric-emptying-slowing effect of GLP-1s is therefore less pronounced.

Despite the altered anatomy, GLP-1 receptor agonists work in post-bariatric patients. They produce additional weight loss when added to a stalled or regaining post-bariatric patient, and they remain effective for type 2 diabetes control. Injection sites and dosing are unchanged. Oral semaglutide (Rybelsus) has not been studied specifically in bariatric patients and is generally avoided after RYGB because the duodenum bypass changes its absorption pathway.

Surgeons typically hold the GLP-1 for 1 week before any major surgery, bariatric or not, to reduce aspiration risk from retained food in the stomach.

Alcohol

Alcohol is not metabolically incompatible with GLP-1s. The FDA labels do not list alcohol as a contraindication. The practical issues are different.

Alcohol on a slowed-stomach GLP-1 hits harder and lasts longer than alcohol on a non-GLP-1 stomach. Many patients report needing significantly less alcohol to reach the same effect, sometimes one drink instead of three. This is part of why GLP-1s are now being studied for alcohol use disorder, where they appear to reduce craving and consumption.

Alcohol is also a known cause of hypoglycemia, especially in fasting patients. Combining alcohol with insulin or a sulfonylurea on top of a GLP-1 increases hypoglycemia risk further. Pancreatitis, a rare but serious GLP-1 adverse event, is also more common in heavy drinkers. Patients with a history of alcohol-related pancreatitis should not start a GLP-1.

Over-the-counter drugs, supplements, and grapefruit

Most OTC medications are safe with GLP-1s. NSAIDs (ibuprofen, naproxen, aspirin) interact with GLP-1s only through delayed absorption, which is not clinically significant. There is no contraindication. Acetaminophen (Tylenol) has a slightly delayed tmax with GLP-1s and is fine to take. Antihistamines (Benadryl, Claritin, Zyrtec, Allegra) have no interaction.

Common supplements:

• Berberine: lowers blood sugar by a different mechanism. Combining with a GLP-1 plus insulin or sulfonylurea raises hypoglycemia risk; combining with a GLP-1 alone is generally fine.
• Omega-3 fish oil: no meaningful interaction. Safe to combine.
• Melatonin: no metabolic interaction. Safe.
• Digestive enzymes (pancrelipase or OTC plant enzymes): often used to mitigate GLP-1-related GI symptoms. No direct interaction. Whether they actually help with GLP-1 nausea is anecdotal.
• Prednisone and other corticosteroids: raise blood glucose and counter the glycemic effect of a GLP-1. Patients on a short course of prednisone for an acute issue often see their fasting glucose rise; this is the steroid, not a GLP-1 failure.

What to do before starting a GLP-1

A clean pre-start medication review prevents most of the avoidable problems. Bring every prescription, every OTC, and every supplement to the appointment, including the ones you take "sometimes." The prescriber will:

1. Identify any sulfonylurea or insulin and plan a dose reduction.
2. Stop any DPP-4 inhibitor.
3. Note any warfarin or other narrow-therapeutic-index drug for closer monitoring.
4. Flag any oral medication that requires a strict absorption window (Rybelsus, levothyroxine, certain HIV antivirals, certain seizure medications).
5. Confirm no history of pancreatitis, gastroparesis, or medullary thyroid cancer (the absolute contraindications, not interactions but worth checking together).

After initiation, the highest-yield safety habit is keeping a single up-to-date medication list, including dose and timing, that you can hand to any new prescriber. GLP-1 interactions are usually mild on paper, but the patients who get into trouble are usually the ones whose right hand prescribed something the left hand did not know about.

Frequently asked questions about GLP-1 drug interactions

Is GLP-1 safe with other medications?

Most medications are safe to take with a GLP-1. The main exceptions to watch are insulin and sulfonylureas (hypoglycemia risk), warfarin (delayed absorption, monitor INR), and oral drugs with strict absorption windows like Rybelsus itself or levothyroxine with Rybelsus.

Are OTC medications safe with GLP-1?

Almost all OTC medications are safe with GLP-1s. Ibuprofen, acetaminophen, antihistamines, and PPIs all have no clinically significant interaction. Absorption may be slightly delayed, which is not a clinical issue for these drugs.

Can you take antibiotics with GLP-1?

Yes. Most antibiotics work normally with a GLP-1. Fluoroquinolones and macrolides can cause hypoglycemia as a class effect, so blood sugar monitoring is wise if you are also on insulin or a sulfonylurea.

Is ibuprofen safe with GLP-1?

Yes. Ibuprofen has no clinically significant interaction with GLP-1 receptor agonists. The usual NSAID cautions (stomach irritation, kidney function, blood pressure) apply independently of the GLP-1.

How do GLP-1s affect oral medication absorption?

GLP-1s slow gastric emptying, which delays tmax and reduces Cmax for most oral drugs. Total absorption (AUC) is usually unchanged, so most drugs do not need dose adjustments. Exceptions are drugs with narrow therapeutic windows like warfarin and lithium.

Can you take prednisone with a GLP-1?

Yes, but prednisone raises blood glucose and may blunt the glycemic effect of the GLP-1 during the steroid course. Weight gain on steroids is also common and partially counters GLP-1 weight loss benefits.

Are GLP-1s safe with birth control pills?

For injectable GLP-1s like Ozempic, Wegovy, Victoza, and Trulicity, oral contraceptive efficacy is preserved and no backup is needed. For tirzepatide (Mounjaro, Zepbound), use a backup method for 4 weeks after each dose increase. For Rybelsus, separate dosing by at least 30 minutes.

Are GLP-1s safe with antidepressants?

Yes. SSRIs (Lexapro, Prozac, Zoloft), SNRIs (Cymbalta, Effexor), and Wellbutrin are commonly prescribed alongside GLP-1s without issue. The serotonin syndrome warning on weight loss GLP-1 labels is precautionary, with no robust real-world signal.

Can I take Lexapro, Prozac, Zoloft, or Cymbalta with a GLP-1?

Yes. These SSRIs and SNRIs are routinely co-prescribed with GLP-1 receptor agonists. No dose adjustment is required for either drug. Tell your prescriber about every medication so they can monitor for the rare theoretical risk of serotonin syndrome.

Can I take Wellbutrin with a GLP-1?

Yes. Wellbutrin (bupropion) is not serotonergic and combines safely with GLP-1s. The bupropion-naltrexone combination (Contrave) is sometimes layered with a GLP-1 in weight loss programs, though this is off-label and should be supervised.

Can I take Adderall, Vyvanse, or Concerta with a GLP-1?

Yes. ADHD stimulants combine safely with GLP-1s. Both classes suppress appetite, so track protein and water intake to avoid undereating. There is no dose adjustment for either drug.

Can I take Abilify, Seroquel, Lamictal, or lithium with a GLP-1?

Yes, but lithium has a narrow therapeutic index and gets absorbed more slowly on a GLP-1. Check a lithium level 4 to 6 weeks after starting the GLP-1. Abilify, Seroquel, and Lamictal need no specific adjustment.

Can I take Topamax with a GLP-1?

Yes. Topiramate is sometimes used off-label for weight loss alongside a GLP-1. No direct interaction. Track hydration and watch for kidney stones, a known topiramate side effect independent of the GLP-1.

Can I take phentermine with a GLP-1?

Some weight loss clinics combine phentermine with a GLP-1 off-label. There is no direct pharmacologic interaction, but the combined appetite suppression is strong and the cardiovascular load of phentermine in patients with hypertension or arrhythmia is a separate concern. Discuss with a prescriber who has experience layering these.

Is GLP-1 plus metformin a standard combination?

Yes. Metformin plus a GLP-1 is the default combination for most patients with type 2 diabetes who need more than monotherapy. No dose change is required for either drug. The GLP-1 does the heavy lifting on weight and glycemia, metformin holds insulin sensitivity steady.

Can you combine GLP-1, metformin, and phentermine?

Some clinics do this off-label for weight loss. There is no direct pharmacologic conflict, but the triple combination amplifies appetite suppression and adds the cardiovascular profile of phentermine. Not a routine first-line approach.

Is GLP-1 plus an SGLT2 inhibitor a good combination?

Yes. The combination is well-supported. SGLT2 inhibitors lower blood glucose by a different mechanism (urinary glucose excretion) and add cardiovascular and kidney benefits. No GLP-1 dose adjustment is needed.

Can you combine a GLP-1 with a DPP-4 inhibitor like Januvia?

No. DPP-4 inhibitors and GLP-1s overlap in mechanism. There is no additive benefit and you are paying for two drugs to do the same job. Stop the DPP-4 when starting a GLP-1.

Can I take warfarin with a GLP-1?

Yes, with closer INR monitoring. Most pharmacokinetic studies show no clinically significant change in INR, but warfarin's narrow therapeutic window justifies weekly INR checks for the first month after starting a GLP-1 or changing the dose.

Can I take melatonin with a GLP-1?

Yes. No metabolic interaction. Melatonin is safe to combine with any GLP-1 receptor agonist.

Can I take insulin with a GLP-1?

Yes, and the combination is common in type 2 diabetes. Reduce basal insulin by about 20 percent at GLP-1 initiation if A1c is at target, and monitor closely for hypoglycemia during the first few weeks.

Can I take blood pressure medication with a GLP-1?

Yes. ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, and diuretics all combine safely with GLP-1s. Watch for blood pressure dropping as weight comes down; many patients eventually reduce or stop antihypertensives.

Can I take berberine with a GLP-1?

Berberine lowers blood sugar through a different mechanism. Combining with a GLP-1 alone is generally fine, but stacking berberine plus a GLP-1 plus insulin or a sulfonylurea raises hypoglycemia risk.

Can I take omega-3 fish oil with a GLP-1?

Yes. No interaction. Fish oil is safe with any GLP-1 receptor agonist.

Should I take digestive enzymes while on a GLP-1?

Some patients use them to mitigate nausea or bloating, but evidence is anecdotal. There is no direct interaction. Pancrelipase prescription enzymes are different and used for specific pancreatic insufficiency, not routine GLP-1 nausea.

Do I need to avoid grapefruit on a GLP-1?

No. GLP-1s are not metabolized by CYP3A4, so grapefruit has no direct effect on them. If you take a statin or another CYP3A4-sensitive drug, the grapefruit warning applies to that drug, not the GLP-1.